Clinical outcome of stereotactic body radiotherapy for localized prostate cancer: long-term results

Stereotactic body radiotherapy (SBRT) is an emerging treatment option which allows for extreme hypofractionation using modern technologies, because the low α/β-ratio favors the use of high dose per fraction in prostate cancer. There is a need for more data about SBRT. We provide a long-term update of SBRT clinical outcome using CyberKnife for the treatment of localized prostate cancer.

This study was based on a retrospective analysis of 43 patients treated with SBRT using CyberKnife for localized prostate cancer (23.3% in low risk, 67.4% in intermediate risk and 9.3% in high risk). The target volume included the prostate with or without the seminal vesicles depending on the risk stratification and uncertainty margins that are kept at 3-5 mm. Total dose of 36.25 Gy in 5 fractions of 7.25 Gy were administered.

43 patients with a median 73.6 months (range, 14 to 119 months) follow-up were analyzed. There was three biochemical failure (BCF). Eight-year BCF free survival and overall survival were 92.0% and 73.1%, respectively. Median PSA decline rates were -0.301, -0.191 and -0.115 ng/mL/month, respectively, for durations of 1, 2 and 3 years after radiotherapy and has remained plateau. Median PSA nadir was 0.27 ng/mL at median 38 months and PSA bounce (median 0.33 ng/mL) occurred in 32.6% (n = 14) of patients at median 19 months after SBRT. There was no grade 3 acute and late toxicity.

Our long-term experience with SBRT using CyberKnife for localized prostate cancer demonstrates favorable efficacy and toxicity.